NEU Share Price History
03 Jun, 2020
Independent Non-Executive Chairman Patrick Donald Davies Just Bought 24% More Shares In Neuren Pharmaceuticals Limited (ASX:NEU)
Whilst it may not be a huge deal, we thought it was good to see that the Neuren Pharmaceuticals Limited (ASX:NEU...
19 May, 2020
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
03 Mar, 2020
ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Rare Pediatric Disease Designation for Trofinetide for the Treatment of Rett Syndrome
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) and Neuren Pharmaceuticals Limited (ASX: NEU) announced today that the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease (RPD) designation to trofinetide for the treatment of Rett syndrome, a serious and rare neurological disorder. Upon FDA approval of a product with RPD designation, the sponsor may be eligible to receive a Priority Review Voucher, which can be used to obtain FDA review of a New Drug Application for another product in an expedited period of six months.
18 Feb, 2020
If You Had Bought Neuren Pharmaceuticals (ASX:NEU) Stock A Year Ago, You Could Pocket A 113% Gain Today
Unless you borrow money to invest, the potential losses are limited. But when you pick a company that is really...
17 Oct, 2019
FDA Grants Orphan Drug Designation for Neuren's NNZ-2591 to Treat Angelman, Phelan-McDermid and Pitt Hopkins Syndromes
Neuren Pharmaceuticals (NEU.AX) today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Neuren’s NNZ-2591 for the treatment of Angelman syndrome, Phelan-McDermid syndrome and Pitt Hopkins syndrome. Neuren Executive Chairman Richard Treagus commented: “Orphan Drug Designation is an important commercial milestone which adds significant value and momentum in respect of our plans to move NNZ-2591 into clinical trials in 2020. This confirms that NNZ-2591 is a valuable asset for Neuren and validates the encouraging preclinical data as well as our plans to develop NNZ-2591 in parallel for these three debilitating childhood disorders with urgent unmet need.
23 Aug, 2019
By buying an index fund, you can roughly match the market return with ease. But if you pick the right individual...